The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin

European Journal of Clinical Pharmacology

Volumn 61, Issue 3, 2005, Pages 189-195

  Xenocostas, Anargyros ^a   Cheung, Wing K ^b   Farrell, Francis ^b   Zakszewski, Cindy ^b   Kelley, Marian ^b   Lutynski, Andrzej ^d,e   Crump, Michael ^d,e   Lipton, Jeffrey H ^d,e   Kiss, Thomas L ^d,e   Lau, Catherine Y ^c   Messner, Hans A ^d,e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Ortho Biotech   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Erythropoietin; Neuroprotective agents

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; HUMAN; KINETICS; MALE; MEMBRANE PERMEABILITY; PRIORITY JOURNAL;

AGED; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 20044369962     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0896-7     Document Type: Article

References (26)

1. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269:19488-19493
2. Juul SE, Anderson DK, Li Y, Christensen RD (1998) Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 43:40-49
3. Dame C, Bartmann P, Wolber EM, Fahnenstich H, Hofmann D, Fandrey J (2000) Erythropoietin gene expression in different areas of the developing human nervous system. Brain Res Dev Brain Res 125:69-74
4. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, Gassmann M (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A 92:3717-3720
5. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8:666-676
6. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76:105-116
7. Juul SE, Stallings SA, Christensen RD (1999) Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 46:543-547
8. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 9:643-651
9. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H (2001) Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 101:271-276
10. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95:4635-4640
11. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y (1999) Effects of erythropoietin on neuronal activity. J Neurochem 72:2565-2572
12. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R (1998) Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253:26-32
13. Brines ML, Ghezzi P, Keenan S, Agnello D, deLanerolle Nihal C, Cerami C., Itri LM, Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:0526-10531
14. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, DeRyck M, Itri L, Prange H, Cerami A, Brines M, Siren AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505
15. Buemi M, Allegra A, Corica F, Floccari F, D'Vella D, Aloisi C, Calapai G, Iacopino G, Frisina N (2000) Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal fluid erythropoietin concentration. Nephrol Dial Transplant 15:422-423
16. Cheung W, Minton N, Gunawardena K (2001) Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 57:411-418
17. Reiber H (1980) The discrimination between different blood-CSF barrier dysfunctions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerebrospinal fluid. J Neurol 224:89-99
18. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, Calapai G, De Vico G, Piedimonte G, Salpietro FM, Tomasello F (2002) Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. PNAS 99:5627-5631
19. Farrel FX, Juul S, Elliot C, Anderson D, Jolliffe, LK (2001) Erythropoietin crosses the blood-brain barrier: an analysis in a nonhuman primate model. Blood 98:148b [abstract]
20. Jumbe NL (2002) Erythropoietic agents as neurotherapeutic agents: what barriers exist? Oncology 16(Suppl 10):S91-S107
21. Long JB, Holaday JW (1987) Blood-brain barrier: endogenous modulation by adrenal-cortical function. Science 227:1580-1583
22. Ziylan YZ, LeFauconnier JM, Bernard G, Bourre JM (1988) Effect of dexamethasone on transport of alpha-aminoisobutyric acid and sucrose across the blood-brain barrier. J Neurochem 51:1338-1342
23. Hedley-Whyte ET, Hsu DW (1986) Effect of dexamethasone on blood brain barrier in the normal mouse. Ann Neurol 19:373-377
24. McMahon FG, Vargas, R, Ryan M, Jain AK, Abels RI, Perry B, and Smith IL (1990) Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76:1718-1722
25. Eprex Product Monograph. Revised version: April 1, 2002 p.23
26. Sowade B, Sowade O, Mocks J, Franke W, Warnke H (1998) The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1:303-314